Drug intelligence / Profile preview

ABNX-100

Development stage: Preclinical
Lead developer: ABIONYX Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

ABNX-100 is a recombinant protein biologic based on apolipoprotein A-I (apoA-I) technology, developed by Abionyx Pharma. It represents a strategic extension of the company's CER-001 platform into the field of ophthalmology. The drug leverages a differentiated mechanism of action focused on lipid regulation and the resolution of inflammation. ABNX-100 is being developed as a systemic treatment for uveitis (intraocular inflammation) and other inflammatory eye diseases, aiming to provide a new generation of therapeutic options in a field where current treatments are often associated with significant side effects.

Other names: recombinant apolipoprotein A-I

Targets

APOA1 (Apolipoprotein A-I)

Beyond the preview

Go deeper on ABNX-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABNX-100.

Explore the full profile